Sidetrade discussed in detail the highly promising acquisition of SHS Viveon. This deal once again confirms Sidetrade's ability to seize M&A opportunities likely to boost its organic growth potential at prices far removed from market standards. #SidetradeALeader
Ric Ruiz Esparza’s Post
More Relevant Posts
-
🚀 Exciting IPO Alert! 🚀 Get ready for a thrilling investment opportunity with the upcoming IPO of Mukka Proteins Limited! 🌟 IPO Details: Company Name: Mukka Proteins Limited Lot Size: 535 Shares || Price Band: ₹26 - ₹28 Open Date: Feb 29 || Close Date: March 4 || Listing Date: March 7 Remarks – Aggressive Investor can Apply For Listing Gain Why Consider Mukka Proteins Limited? 💼 Leading Manufacturer: Specializing in fish protein products crucial for aqua feed, poultry feed, and pet food. 📆 Established in 2003 with over two decades of experience, Mukka Proteins has established itself as a reliable player in the market. 📈 Growth Potential: Ideal for aggressive investors seeking short-term listing gains. 📈 Don't miss out on being a part of Mukka Proteins Limited's growth story! ** The views shared on upcoming IPOs are for educational & informational purposes only and not a substitute for professional investment advice; always consult your financial advisor before making any Investment decisions. For investment guidance and more info, contact us at Money Compound! 📱 8447496480 📩 [email protected] #IPO #InvestmentOpportunity #StockMarket #MukkaProteins #ListingGains #InvestWisely #Finance #Investment #IPOAlert #GrowthPotential #AquaFeed #PoultryFeed #PetFood #AggressiveInvesting #Stocks #Investing101 #MoneyMoves #FinancialFreedom #InvestmentStrategy #StockTrading #StocksToWatch #investmentstrategy
To view or add a comment, sign in
-
-
Business and academic professional | Grocery Retail | Insurance | Leader | Analyst | Project Manager | Lecturer 🍃 Planted Society Board Treasurer 🌿
Interesting read that (even though it illustrates the challenges of the current landscape,) lends hope that the blended space can help soften the decline in plant-based. Thinking outside of one stream (one way to get to the goal v. multiple ways working toward the same goal) has helped open my eyes to the possibility of actually achieving the end result quicker. #BlendedMeat has the potential of shortening the adoption timeline and making impact faster than #PlantBased alone.
💵📉 MYCORENA FILES FOR BANKRUPTCY DUE TO FUNDRAISING DIFFICULTIES On Saturday, Mycorena announced that it has filed for bankruptcy, citing “significant financial challenges”. The decision followed the mycoprotein producer’s unsuccessful attempts to raise capital for its Series B round, and came a month after it discontinued plans for a commercial-scale factory. Mycorena, which sells fungi-based proteins and fats to food manufacturers, has been facing financial challenges for the last two years. “Our team has explored every possible avenue to save this pioneering company,” chairman Tore Sveälv after appointing law firm Advokatfirman Lindahl KB as trustee to administer the bankruptcy process. However, all hope is not lost, as the company believes renewed investment can revive the brand. To do so, some of Mycorena’s former shareholders are now building a new consortium, and their ambition is to buy back the bankruptcy estate and reinstate the company’s operations, giving it a “fresh restart”, founder and CEO Ramkumar Nair tells Green Queen. “We are also glad to see that many new investors also see a great opportunity to join that consortium now, with the possibility of them onboarding a fresh start for Mycorena, leveraging on all the value and learnings we have had for the past years,” adds Nair, who founded the company in 2017 based on his PhD research project. To date, Mycorena has raised over €35M in equity funding, including what was at the time the largest Series A for a Nordic alternative protein startup. It currently operates a demonstration facility in Gothenburg, opened in 2021 and built on the success of Promyc, its flagship mycoprotein ingredient. Nair believes the mycoprotein segment is here to stay. Indeed, despite even Quorn Foods – the largest mycoprotein producer – facing financial challenges, it is rejigging things by entering the blended meat space. Scottish-Dutch ENOUGH recently closed a €40M Series C round, while Finland’s Enifer received €24M to open a commercial-scale facility. And in the US, The Better Meat Co. obtained a ‘no further questions’ letter from the FDA just last week. More information in the full article: https://lnkd.in/eF5jGqrs #GreenQueen #altprotein #sustainability #precisionfermentation #mycoprotein #foodsystems
To view or add a comment, sign in
-
-
Personal Portfolio Manager | Virtual Portfolio Manager | Swing Trader | Helping people for managing funds. Mission:- Building the financially literate Bharat.
Rossari Biotech A Cup with Handle Formation, Break-out, Break-out confirmation, then retracement. Good business and financials. 👍 #RossariBiotechinvestment #Biotechinvestment #RossariInvestment #InvestinginBiotech #BiotechOpportunity #GrowthinBiotech #RossariInvest #BiotechInvestor #InvestmentOpportunity #RossariBiotech
To view or add a comment, sign in
-
-
PulteGroup ( $PHM ) Piotroski F Score: 5. HEALTHY: Average experts consensus on PulteGroup has changed. Analysts have now less confidence in PulteGroup as compared to a month ago. The current buy or sell recommendation of 18 analysts is Strong Buy. PulteGroup employs about 6.4 K people. The company is managed by 44 executives with a total tenure of roughly 273 years, averaging almost 6.0 years of service per executive, having 145.05 employees per reported executive. PulteGroup is selling for 115.62. This is 1.24% increase. Opened at 114.2. https://lnkd.in/eTGPwiA5 #hotstocks #investing #trading
To view or add a comment, sign in
-
#ShareholderAlert: Wolf Popper LLP Continues its #Investigation on Behalf of #Investors in Harmony Biosciences Holdings, Inc. ($HRMY) #joinclassaction #securitieslitigation #leadplaintiff #classactionlawsuitlawsuit #securitiesclassaction #classactions #shareholderactivism #lawfirm 'Link in Comments'
To view or add a comment, sign in
-
-
#MidCapPE #CarveOuts #CrossBorderM&A Thanks to all! On the legal Buyerside in particular to #RobertOberlies and #RoxanneThorelli from #FredLaw.
💥 We are proud to announce the successful closing of the first transaction within our LEO III fund with the acquisition of Ampack GmbH and Osgood Industries, LLC from CVC-backed Syntegon. 👉 Ampack and Osgood Industries specialize in the engineering, assembly, and servicing of food liquid packaging machines, focusing on fill and seal technology for cups and bottles. Leading in the food packaging market for liquid and dairy products, especially in aseptic areas, they serve all hygienic segments. With over 290 employees in Europe (Königsbrunn, DE) and North America (Oldsmar, US), they have installed more than 1,500 machines for renowned customers. Holding over 100 active patents and focusing on sustainable solutions, their strategic approach fits perfectly with DUBAG Group's strategic vision for investing in promising ventures. 📰 Read more about the transaction on our website: https://lnkd.in/dYVF75V6 DUBAG Group Deal Team Dr. Michael Schumann, Emanuel Cattanei, Marco Thoni, Fabian Hilke 🤝🏼 Special thanks for the support of: Dr. Andreas Lenz, Bastian Rieck, Dr. Julius Wedemeyer, LL.M. & the team of HEUKING Matthias Riemann, Barbara Siegert, Kai-Markus Hock, Cäcilie Cosima Fisseler, & the team of Munich Strategy Sandro Schwenke LL.M., Julia Loncar, Alexander Mayberry & the team of BDO Marc Bernstein, Gregor Nowak, Kristopher Lazarz & the team of Kroll Christian Wolber, Özay Süerdem, Konstantin Narykov, CEIM & the team of Gracher Kredit- und Kautionsmakler GmbH & Co. KG Alfred Garbe & the team of AB SAGAX Angelo Haplea & the team of TPSH Versicherungsmakler GmbH and to the team of Rautenberg & Company for facilitating the transaction #PrivateEquity #Deal #Carveout #Specialsituations
To view or add a comment, sign in
-
At Cavendish, we believe AIM is a great platform for owners of businesses as it allows them to source additional capital whilst maintaining an element of control. It also allows the flexibility for the founders to sell down their stakes in a controlled manner. Cavendish has been involved in managing multiple sell downs over recent years and completed two in life sciences in last month, realising £11m in aggregate, both at a discount of less than 5% to the mid price. This is despite ongoing challenges in equity markets. These two sell downs, in Bioventix (£2.4m) and hVIVO (£8.4m) were both oversubscribed and allowed us to introduce a number of high quality investors to the register. Geoff Nash, Corporate Finance Director commented: “We have an ongoing desire to broaden the shareholder base of all our corporate clients and were pleased to be able to do so for both of these fantastic businesses – we brought Bioventix to AIM with a market cap of £28m (now £260m) and started working with hVIVO (then Open Orphan) in mid-2020 when the market capitalisation was £70m (£180m today). If we can help your business, please do get in touch.” #lifesciences #healthcare #growthbusiness #capitalmarkets #AIM
To view or add a comment, sign in
-
Investing in #cannabis or still thinking? Here's the one guy who will save you some pain and will shorten your learning curve - join Stephen Abraham at Benzinga Cannabis for some valuable insights and best practices #notjustvapor
Join our CFO Stephen Abraham at Benzinga's Cannabis Capital Conference for a deep dive on Portfolio Diversification where he will share strategies on Including Cannabis In Your Investment Mix - April 16th, 1:00 - 1:25 PM, use code BLINC20 for a discount on tickets at- https://buff.ly/4cURcVV We look forward to seeing you in Florida! #notjustvapor #poweredbyblinc -- #cannabiscommunity #cannabisbusiness #cannabisindustry #vape #event #tradeshow #networking #innovation #business
To view or add a comment, sign in
-
-
Two great examples of our clients’ continued growth stories on AIM and how recent sell downs have broadened the shareholder base for these firms. #growthbusiness #capitalmarkets #ukeconomy
At Cavendish, we believe AIM is a great platform for owners of businesses as it allows them to source additional capital whilst maintaining an element of control. It also allows the flexibility for the founders to sell down their stakes in a controlled manner. Cavendish has been involved in managing multiple sell downs over recent years and completed two in life sciences in last month, realising £11m in aggregate, both at a discount of less than 5% to the mid price. This is despite ongoing challenges in equity markets. These two sell downs, in Bioventix (£2.4m) and hVIVO (£8.4m) were both oversubscribed and allowed us to introduce a number of high quality investors to the register. Geoff Nash, Corporate Finance Director commented: “We have an ongoing desire to broaden the shareholder base of all our corporate clients and were pleased to be able to do so for both of these fantastic businesses – we brought Bioventix to AIM with a market cap of £28m (now £260m) and started working with hVIVO (then Open Orphan) in mid-2020 when the market capitalisation was £70m (£180m today). If we can help your business, please do get in touch.” #lifesciences #healthcare #growthbusiness #capitalmarkets #AIM
To view or add a comment, sign in
-
Life Sciences Commentary Geoff Nash, Director at Cavendish comments: "We all look forward to a more positive 2024 after two of most challenging years in equity markets ever experienced. Despite this, at Cavendish we continue to deliver for our clients. Since January 2022 we have raised over £105m across 13 secondaries and an IPO in feed additives. This represents over 25% of all activity in the life sciences sector where approximately £400m* was raised in 2022/3. We have lots to execute on in 2024 and look forward to growing our healthcare franchise further.” *excludes fundings sub £2m #lifesciences #healthcare #growthbusiness #capitalmarkets
To view or add a comment, sign in